Man Group plc Invests $3.60 Million in The Chemours Company (NYSE:CC)

Man Group plc purchased a new stake in The Chemours Company (NYSE:CC - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 212,700 shares of the specialty chemicals company's stock, valued at approximately $3,595,000. Man Group plc owned 0.14% of Chemours as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Quadrant Capital Group LLC grew its holdings in shares of Chemours by 100.4% in the 4th quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock valued at $38,000 after buying an additional 1,119 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in shares of Chemours in the 4th quarter valued at $48,000. Itau Unibanco Holding S.A. grew its holdings in shares of Chemours by 39.3% in the 4th quarter. Itau Unibanco Holding S.A. now owns 3,554 shares of the specialty chemicals company's stock valued at $60,000 after buying an additional 1,003 shares during the period. KBC Group NV grew its holdings in shares of Chemours by 38.2% in the 4th quarter. KBC Group NV now owns 6,176 shares of the specialty chemicals company's stock valued at $104,000 after buying an additional 1,708 shares during the period. Finally, Sterling Capital Management LLC grew its holdings in shares of Chemours by 54.8% in the 4th quarter. Sterling Capital Management LLC now owns 8,453 shares of the specialty chemicals company's stock valued at $143,000 after buying an additional 2,991 shares during the period. Institutional investors and hedge funds own 76.26% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on CC shares. The Goldman Sachs Group cut their price objective on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 14th. BMO Capital Markets cut their price objective on shares of Chemours from $34.00 to $27.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 19th. Mizuho set a $15.00 price objective on shares of Chemours in a research report on Tuesday, April 15th. Morgan Stanley cut their price objective on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a research report on Monday, May 12th. Finally, UBS Group cut their price objective on shares of Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $17.56.

Insiders Place Their Bets

In other news, CFO Shane Hostetter acquired 4,450 shares of the stock in a transaction dated Monday, May 19th. The shares were bought at an average cost of $11.28 per share, for a total transaction of $50,196.00. Following the purchase, the chief financial officer now directly owns 59,694 shares of the company's stock, valued at approximately $673,348.32. This trade represents a 8.06% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.47% of the company's stock.

Chemours Stock Up 3.0%

NYSE:CC traded up $0.31 on Tuesday, hitting $10.61. 3,776,394 shares of the company's stock were exchanged, compared to its average volume of 2,098,482. The firm has a 50-day moving average price of $11.80 and a 200-day moving average price of $15.85. The company has a debt-to-equity ratio of 6.70, a current ratio of 1.68 and a quick ratio of 0.92. The Chemours Company has a 52 week low of $9.33 and a 52 week high of $26.98. The company has a market cap of $1.59 billion, a P/E ratio of 18.61 and a beta of 1.76.

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.06). Chemours had a return on equity of 26.54% and a net margin of 1.51%. The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same period last year, the firm earned $0.32 earnings per share. The company's quarterly revenue was up .4% compared to the same quarter last year. As a group, analysts expect that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Dividend Announcement

The firm also recently declared a dividend, which will be paid on Monday, June 16th. Shareholders of record on Monday, May 19th will be given a dividend of $0.0875 per share. The ex-dividend date is Friday, May 16th. This represents a yield of 3.17%. Chemours's dividend payout ratio (DPR) is presently 175.00%.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.